SYRE Spyre Therapeutics, Inc. Common Stock Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
15:13
Jun 22
Jun 22
Skeptical about HLE mAb valuations; questions high price tags for SYRE and ORKA.
MED
15:57
Jun 20
Jun 20
Short SYRE — faces more biosimilar competition than peers, pharmas already developing competing extended half-life IL23s and a4b7 internally, requires massive dilutive capital raises for long combination trials, no credible M&A acquirer identified, yet trades at a multi-billion premium that makes no structural sense.
MED
15:35
Jun 20
Jun 20
The author questions who would buy ORKA or SYRE given ABBV's extended half-life IL-23, implying competitive risk but without a clear position or forward call.
LOW
13:50
Jun 15
Jun 15
Author notes Spyre's market cap and high share count but does not state a personal position or forward call, only a factual observation.
LOW
13:33
Jun 15
Jun 15
SYRE trades at a comparable market cap to a fully post-Phase 3 competitor despite being 6-8 years behind in development with undifferentiated me-too pipeline assets — author implies significant overvaluation relative to clinical stage and pipeline quality.
MED
12:54
Jun 15
Jun 15
Short SYRE — Phase 2a open-label data fails to clear blinded clinical remission benchmarks already set by same-MOA drugs in Phase 3, and the press release omits anti-drug antibody (ADA) disclosure, a known class-killing risk for TL1a inhibitors, suggesting either concealment or a looming data problem.
MED
12:31
Jun 15
Jun 15
Short SYRE — Phase 2a open-label data fails to clear the blinded clinical remission benchmarks already set by same-MOA competitors in Phase 3, suggesting the stock is being propped up on scientifically inferior data with no durable catalyst to justify current valuation.
MED
12:13
Jun 10
Jun 10
Author speculates about potential acquisition targets for Sanofi but uses hedged language and does not state a personal position or directional view.
LOW
15:10
Jun 04
Jun 04
The author compares market caps of SYRE and ABVX to highlight a perceived valuation disparity but does not state a personal position or forward call.
LOW
13:38
May 19
May 19
Buy SYRE, ORKA, and APGE as the triple combination appears undervalued relative to alternatives, with potential upside from oncology inclusion.
HIGH
12:41
May 19
May 19
Avoid SYRE, ORKA, and APGE due to overvaluation vs. a private competitor with superior bispecific platform, broader pipeline, and lower trial risk; the author questions the durability of their clinical data and rationale for separate companies.
HIGH
12:07
May 19
May 19
Bearish view on SYRE due to an extended commercialization timeline (2034+), significant future dilution, and me-too biosimilar targets that make the current $7.5B market cap unsustainable even with 15% annual return assumptions.
HIGH
11:26
May 19
May 19
The author questions the feasibility of lengthy and costly Phase 3 UC maintenance trials for SYRE, implying skepticism about the drug's timeline and competitive edge despite a $7.5B open-label data asset.
MED
16:10
May 07
May 07
The tweet lists four biotech tickers with no directional commentary or forward-looking thesis, merely sharing a link without expressing a bullish or bearish view.
HIGH
18:11
May 01
May 01
Bearish view on SYRE because its current ~$8.2B valuation is unjustified by only open label data; even a 33% drop leaves an inflated ~$5.5B cap, implying further downside.
HIGH
18:07
May 01
May 01
Adam May notes ORKA dropped 30% from Monday's high and links to SYRE, but provides no forward-looking opinion or trade thesis.
HIGH
19:00
Apr 30
Apr 30
Adam May suggests ABVX's potential $15B deal with a novel MOA post-phase 3 offers a better risk-weighted return than SYRE's me-too pipeline, implying SYRE is overvalued at over $8B.
18:38
Apr 30
Apr 30
Bearish view on SYRE as its $8B+ valuation is unjustified compared to ABVX; SYRE’s me-too MOA, open-label P2a data, impending generic competition, and multiple rivals do not warrant a premium over ABVX’s breakthrough P3 with zero intra-MoA competition.
HIGH
16:43
Apr 29
Apr 29
Bearish view on SYRE because ABBV's single bispecific antibody for IL23/TL1A undercuts SYRE's two-drug combo, requiring SYRE to run expensive multi-arm trials while ABBV breezes through cheaper, faster development.
HIGH
16:10
Apr 29
Apr 29
Adam May compares SYRE and the YTE group to a poorly received Indiana Jones film, implying a negative analogy without a clear forward-looking directional call.
HIGH
15:21
Apr 29
Apr 29
SYRE's market cap nearing ABVX despite having only me-too pipeline; argues valuation disconnect suggests overvaluation, implying a short opportunity.
HIGH
14:57
Apr 29
Apr 29
Reports SYRE surged to $8B market cap on positive open-label UC trial data; no directional stance from speaker.
HIGH
10:57
Apr 29
Apr 29
Bearish view on SYRE; open-label UC data offers no edge over existing drugs, yet stock rallied >100% — valuation detached from fundamental innovation, relying on financial engineering.
HIGH
23:51
Apr 28
Apr 28
Avoid ORKA and SYRE because recent data readouts only confirmed expected results after stocks already rallied >100%, indicating no new catalyst and potential overvaluation.
HIGH
13:32
Apr 18
Apr 18
Bearish view on SYRE as the true market capitalization exceeds $7 billion when accounting for uncounted Series A preferred shares, making the valuation significantly worse than perceived.
HIGH
12:26
Apr 18
Apr 18
Fade the recent $3B market cap surge in SYRE, as the drug's target will face generic competition by the time it actually reaches the market in over five years.
HIGH
13:57
Apr 17
Apr 17
Bearish view on SYRE as its recent multi-billion dollar valuation surge is fundamentally unjustified, relying on open-label data for an already widely used mechanism of action amid broader sector froth.
HIGH
15:02
Apr 13
Apr 13
Bearish view on SYRE as the recent >$1B market cap addition is fundamentally unjustified, driven only by small, open-label data for a non-novel mechanism of action.
HIGH
13:35
Apr 13
Apr 13
Short SYRE to fade the massive 40% opening gap up, anticipating mean reversion or exhaustion of the initial buying pressure.
HIGH
12:21
Apr 13
Apr 13
Fade SYRE's Phase 2a data release, as the study's open-label design without a placebo group makes the results unreliable compared to established blinded studies.
HIGH
About SYRE Analyst Coverage
Buzzberg tracks SYRE (Spyre Therapeutics, Inc. Common Stock) across 1 sources. 0 bullish vs 6 bearish calls from 1 analysts. Sentiment: mixed to bearish. 30 total trade ideas tracked. Latest voices: A May MD.